|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Current assets: | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Collaboration receivable | |||||||||||||||
| Prepaids and other current assets | |||||||||||||||
| Total current assets | |||||||||||||||
| Fixed assets, net | |||||||||||||||
| Other assets | |||||||||||||||
| Total assets | |||||||||||||||
| Liabilities and Stockholders' Equity | |||||||||||||||
| Current liabilities: | |||||||||||||||
| Accounts payable | |||||||||||||||
| Accrued expenses | |||||||||||||||
| Deferred collaboration revenue | |||||||||||||||
| Total current liabilities | |||||||||||||||
| Total liabilities | |||||||||||||||
| Stockholders' equity: | |||||||||||||||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 23,457,849 and 20,934,456 shares issued and outstanding as of June 30, 2026 or December 31, 2025, respectively | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Subscription receivable | |||||||||||||||
| Accumulated deficit | |||||||||||||||
| Total stockholders' equity | |||||||||||||||
| Total liabilities and stockholders' equity | |||||||||||||||
Loading...
